P2-01 TAR-200 IN PATIENTS WITH BACILLUS CALMETTE–GUÉRIN-UNRESPONSIVE HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER: RESULTS FROM SUNRISE-1 STUDY

Overview of attention for article published in The Journal of Urology, May 2024

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news: 42 news outlets
twitter: 1 X user

patent: 2 patents
guideline: 1 clinical guideline source

Readers on

mendeley: 9 Mendeley

So far, Altmetric has seen 42 news stories from 42 outlets.

New Bladder Preservation Strategies in Urothelial Carcinoma of the Bladder (18.04.2025)

Deutsches Ärzteblatt, 05 Jun 2025

INTERNATIONAL STUDIEREN Review article Dtsch Arztebl Int 2025; 122: 211-8. DOI: 10.3238/arztebl.m2025.0014 ; Bhmer, D; Bolenz, C…

TAR-200 Leads to Lasting Responses in BCG-Unresponsive Bladder Cancer

Oncology Nursing News, 09 May 2024

Rapid, durable responses were observed in patients with Bacillus Calmette–Guérin-unresponsive high-risk non–muscle-invasive…

Lasting Responses Observed With TAR-200 in BCG-Unresponsive NMIBC

Cancer Network, 07 May 2024

“In conclusion, TAR-200 monotherapy provides a rapid and high CR rate [for patients with] Bacillus Calmette-Guérin–unresponsive…

TAR-200 Monotherapy Has 82.8% Complete Response Rate in BCG-Unresponsive HR-NMIBC

AJMC, 04 May 2024

Updated results from SunRISe-1—an ongoing open-label phase 2b study—demonstrated the effectiveness and safety of TAR-200 when…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 38 additional news stories.